2 型糖尿病的药物基因组学研究进展：系统综述。
Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview.
机构信息
Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA.
Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA.
出版信息
Diabetes Metab Syndr. 2021 Sep-Oct;15(5):102239. doi: 10.1016/j.dsx.2021.102239. Epub 2021 Aug 3.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a prevalent disease with incidences increasing globally at a rapid rate. The goal of T2DM treatment is to control glucose levels and prevent the aggravation of glycemic symptoms.
TREATMENT OPTIONS
T2DM regimen include metformin as the first-line, with sulfonylurea, thiazolidinedione (TZD), GLP-1, DPP4I, and SGLT2 inhibitor as the second-line treatment options. However, even with a multitude of choices, patient-to-patient variability due to pharmacogenomic differences still prevail.
CONCLUSION
This review aims to discuss the responses of the major T2DM medications influenced by pharmacogenomics and investigate improved personalized therapy for T2DM patients.
简介
2 型糖尿病（T2DM）是一种常见疾病，其发病率在全球范围内迅速上升。T2DM 的治疗目标是控制血糖水平，防止血糖症状恶化。
治疗选择
T2DM 治疗方案包括二甲双胍作为一线治疗药物，磺酰脲类、噻唑烷二酮（TZD）、GLP-1、DPP4I 和 SGLT2 抑制剂作为二线治疗选择。然而，即使有多种选择，由于药物基因组学差异导致的患者间变异性仍然存在。
结论
本综述旨在讨论受药物基因组学影响的主要 T2DM 药物的反应，并研究改善 T2DM 患者的个体化治疗。
Zotero 插件